- Inbunden (Hardback)
- Antal sidor
- 2nd ed. 2014
- Springer-Verlag New York Inc.
- Rudek, Michelle A. (ed.), Chau, Cindy H. (ed.), Figg, William D. (ed.), McLeod, Howard L. (ed.)
- 46 illus in color XVIII, 900P145 illus 99 schwarz-weiße und 46 farbige Abbildungen
- 46 Illustrations, color; 99 Illustrations, black and white; IX, 836 p. 145 illus., 46 illus. in colo
- 273 x 190 x 50 mm
- Antal komponenter
- 1 Hardback
- 2177 g
Du kanske gillar
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
Fri frakt inom Sverige för privatpersoner.
Fler böcker av författarna
William D Figg, Judah Folkman
Dr. Judah Folkman is considered the "father of angiogenesis." Because of Folkman's discovery and research, the possibilities of angiogenic therapy have broadened beyond cancer to many noncancerous diseases. Angiogenesis: An Integrative A...
Drug Management of Prostate Cancer
William D Figg, Cindy H Chau, Eric J Small
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It...
Recensioner i media
"...an invaluable overview of the experimental and clinical processes that lead to anticancer drugs, creating a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials." - Tumori
Bloggat om Handbook of Anticancer Pharmacokinetics a...
Dr. Michelle Rudek received her BS in Pharmacy from the University of Pittsburgh and her dual Pharm.D., Ph.D. from Virginia Commonwealth University in a joint clinical pharmacology/oncology program with the National Cancer Institute. Dr. Rudek joined Johns Hopkins University in 2001 and is currently an Associate Professor of Oncology and Director of the Analytical Pharmacology Core Laboratory. Her research program is focused on clinical pharmacology with a focus on early phase drug development and special populations including AIDS malignancy and organ dysfunction. Dr. Cindy H. Chau received her BS in Molecular, Cell, and Developmental Biology from UCLA and her Pharm.D. and Ph.D. (in Molecular Pharmacology and Toxicology) dual degrees from the University of Southern California School of Pharmacy as a National Institutes of Health (NIH) predoctoral fellow. She was the recipient of the NIH National Research Service Award. Dr. Chau completed a postdoctoral fellowship at the NIH, joining the National Cancer Institute in 2004 and is currently a research scientist within the Medical Oncology Branch, Center for Cancer Research. Dr. William Douglas Figg received his B.S. (Hon) from Georgetown College, his B.S. in Pharmacy from Samford University and his Pharm.D. from Auburn University. He completed his clinical pharmacy internship at the University of Alabama at Birmingham Hospital and his fellowship in drug development at the University of North Carolina-Chapel Hill. Dr. Figg also received an M.B.A. degree from a combined program at Columbia University and London Business School. He joined the Medical Oncology Branch, National Cancer Institute, National Institutes of Health in 1992. He has patented more than 80 new anticancer agents and four pharmacogenetic tests. Dr. Howard McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr. McLeod holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center. Dr McLeod is chair of the NHGRI eMERGE network external scientific panel and is a member of the FDA committee on Clinical Pharmacology. He is a member of the NIH NHGRI Advisory Council. Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world.
Molecular Targets Annunziata, Christina M. (et al.) Preclinical Screening for New Anticancer Agents Burger, Angelika M. (et al.) Natural Product Screening McKee, Tawnya C. (et al.) Defining the Starting Dose: Should It Be mg/kg, mg/m Gao, Bo (et al.) Phase 0 Trials in Oncology Kummar, Shivaani (et al.) Phase I Trials in Oncology: Design and Endpoints Glen, Hilary (et al.) Quantitative Analytical Methods: Development and Clinical Considerations Gardner, Erin R. Validation and Control of Bioanalytical Methods Karnes, H. Thomas (et al.) Anticancer Clinical Pharmacology Overview Dandamudi, Uday B. (et al.) Pharmacokinetic Modeling Li, Jing (et al.) Pharmacometrics Brar, Satjit S. (et al.) Pharmacodynamic Modeling Bauer, Kenneth S. (et al.) Protein Binding Sparreboom, Alex (et al.) Metabolism (Non-CYP Enzymes) Jamieson, David (et al.) Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms Patel, Jai N. (et al.) Cytochrome P450 Ando, Yuichi Polymorphisms in Genes of Drug Targets and Metabolism Bohanes, Pierre (et al.) DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance Reed, Eddie (et al.) Drug Interactions Rivory, Laurent P. ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition Massey, Paul R. (et al.) Solute Carriers Ho, Richard H. (et al.) High-Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics English, Bevin C. (et al.) Intrathecal Administration Kilburn, Lindsay B. (et al.) Microdialysis Combest, Austin J. (et al.) Regional Drug Delivery for Inoperable Pulmonary Malignancies Schrump, David S. Blood-Brain Barrier and CNS Malignancy Balmanoukian, Ani (et al.) Radiation and Altering Clinical Pharmacology Smart, DeeDee (et al.) Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment Madan, Ravi A. (et al.) Recombinant Immunotoxins Kreitman, Robert J. Monoclonal Antibodies Bai, Shuang (et al.) Clinical Pharmacology in Pediatrics Tagen, Michael (et al.) Clinical Pharmacology in the Older Adult Slattum, Patricia W. (et al.) Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers, and Suggestions for Future Trials Kummar, Shivaani (et al.) Drug Formulations: How these Affects Anticancer Drug Lagas, Jurjen S. (et al.) Nanotechnology in Cancer Janat-Amsbury, Margit M. (et al.) Imaging in Drug Development Kurdziel, Karen A. (et al.) Exposure-Response Relationships of Anticancer Agents: Application in Drug Development and Drug Label Rahman, Atiqur The Role of Phase III Trials in Modern Drug Development Murphy, Janet E. (et al.) Clinical Trial Designs for Approval of New Anticancer Agents Chadha, Manpreet K. (et al.) Clinical Pharmacogenetics Sachidanandam, Kamakshi (et al.)